胆囊癌中微小RNA的功能及临床价值研究进展

摘要/Abstract

摘要： 胆囊癌(gallbladder carcinoma,GBC)是临床常见的消化道恶性肿瘤,具有起病隐匿、预后差的特点,导致了十分严重的社会及医疗负担。GBC的致病机制十分复杂,临床上缺少早期预警及临床预后的有效指标。对于无法接受手术治疗的患者,临床上也缺乏有效的特异性治疗方法,患者通常预后较差。微小RNA(microRNA,miRNA)是不具有编码功能的微小RNA,其主要通过直接抑制靶向基因的表达。大量研究显示,特异性miRNA在GBC的致病及进展中发挥着重要调控作用。同时,随着循证医学证据的积累,特异性miRNA在GBC的早期诊断及临床预后中也显示出了较为优良的临床价值。虽然靶向miRNA的GBC治疗方法目前仍停留在基础研究阶段,但是也为开发针对GBC的有效治疗方法提供了重要参考。

关键词: 胆囊癌, 微小RNA, 诊断, 预后, 治疗

陈茜, 朱鹏. 胆囊癌中微小RNA的功能及临床价值研究进展[J]. 肝脏, 2024, 29(1): 126-130.

参考文献

[1] Siegel R L,Miller K D,Wagle N S,et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
[2] 单天昊,安澜,徐梦圆,et al. 2020年全球肝癌和胆囊癌发病死亡分析[J]. 肝癌电子杂志, 2022, 9(4): 46-51.
[3] Hrudka J,Sticova E. Cholangiocarcinoma: a pathologists point of view[J]. Rozhl Chir, 2022, 101(10): 478-487.
[4] Jiang Y,Jiang L,Li F,et al. The epidemiological trends of biliary tract cancers in the United States of America[J]. BMC Gastroenterol, 2022, 22(1): 546.
[5] Ganeshan D,Kambadakone A,Nikolaidis P,et al. Current update on gallbladder carcinoma[J]. Abdom Radiol (NY), 2021, 46(6): 2474-2489.
[6] Lee W,Chandan V S. Gallbladder carcinomas: review and updates on morphology, immunohistochemistry, and staging[J]. Hum Pathol, 2022.
[7] Matulic M,Grskovic P,Petrovic A,et al. miRNA in Molecular Diagnostics[J]. Bioengineering (Basel), 2022, 9(9).
[8] Naeli P,Pourhanifeh M H,Karimzadeh M R,et al. Circular RNAs and gastrointestinal cancers: Epigenetic regulators with a prognostic and therapeutic role[J]. Crit Rev Oncol Hematol, 2020, 145: 102854.
[9] Neuzillet C,Artru P,Assenat E,et al. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective[J]. Target Oncol, 2023, 18(1): 51-76.
[10] Su L,Zhang J,Zhang X,et al. Identification of cell cycle as the critical pathway modulated by exosome-derived microRNAs in gallbladder carcinoma[J]. Med Oncol, 2021, 38(12): 141.
[11] Cao J,Shao H,Hu J,et al. Identification of invasion-metastasis associated MiRNAs in gallbladder cancer by bioinformatics and experimental validation[J]. J Transl Med, 2022, 20(1): 188.
[12] Tong L,Cheng J,Zuo H,et al. MicroRNA-197 promotes proliferation and inhibits apoptosis of gallbladder cancer cells by targeting insulin-like growth factor-binding protein 3[J]. Adv Clin Exp Med, 2021, 30(7): 661-672.
[13] Ouyang B,Pan N,Zhang H,et al. miR146b5p inhibits tumorigenesis and metastasis of gallbladder cancer by targeting Tolllike receptor 4 via the nuclear factorkappaB pathway[J]. Oncol Rep, 2021, 45(4).
[14] Wang J,Jin Y,Li S,et al. Identification of microRNAs associated with the survival of patients with gallbladder carcinoma[J]. J Int Med Res, 2020, 48(5): 300060520918061.
[15] Zhang J,Hu Z,Wen C,et al. MicroRNA-182 promotes epithelial-mesenchymal transition by targeting FOXN3 in gallbladder cancer[J]. Oncol Lett, 2021, 21(3): 200.
[16] Hu X,Zhang J,Bu J,et al. MiR-4733-5p promotes gallbladder carcinoma progression via directly targeting kruppel like factor 7[J]. Bioengineered, 2022, 13(4): 10691-10706.
[17] Jiang Z B,Ma B Q,Feng Z,et al. miR-365 inhibits the progression of gallbladder carcinoma and predicts the prognosis of Gallbladder carcinoma patients[J]. Cell Cycle, 2021, 20(3): 308-319.
[18] Xie J,Liao Z,Sun C,et al. Impact of Primary Tumor Resection on Survival of Patients with Metastatic Gallbladder Carcinoma: A Population-Based, PropensityMatched Study[J]. Med Sci Monit, 2022, 28: e934447.
[19] 曹丽君,李伟,余海龙,et al. 胆囊癌的临床及影像征象分析[J]. 肝脏, 2021, 26(6): 650-654.
[20] Yang P,Song F,Yang X,et al. Exosomal MicroRNA signature acts as an efficient biomarker for non-invasive diagnosis of gallbladder carcinoma[J]. iScience, 2022, 25(9): 104816.
[21] 庄琰,任文妍,杜森,et al. 多层螺旋CT联合血清lncRNA TUG1和miR-29c-3p检测在胆囊癌诊断中的应用[J]. 临床肿瘤学杂志, 2022, 27(11): 1004-1008.
[22] Chen J,Yu Y,Chen X,et al. MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma[J]. Cell Prolif, 2018, 51(6): e12510.
[23] Lv Y P,Shi W,Liu H X,et al. Identification of miR-146b-5p in tissues as a novel biomarker for prognosis of gallbladder carcinoma[J]. Eur Rev Med Pharmacol Sci, 2017, 21(3): 518-522.
[24] Zhang B,Cui H,Sun Y,et al. Up-regulation of miR-204 inhibits proliferation, invasion and apoptosis of gallbladder cancer cells by targeting Notch2[J]. Aging (Albany NY), 2021, 13(2): 2941-2958.
[25] 徐顺林,格桑志玛,土登·降拥尼玛,et al. 胆囊癌患者血清miRNA-187和miRNA-143表达及与临床病理特征和预后的关系[J]. 解放军医药杂志, 2021, 33(5): 43-47.
[26] Ahmed S H,Usmani S U R,Mushtaq R,et al. Role of laparoscopic surgery in the management of gallbladder cancer: Systematic review & meta-analysis[J]. Am J Surg, 2023.
[27] Zhu H,Chen Z,Yu J,et al. MiR-195-5p suppresses the proliferation, migration, and invasion of gallbladder cancer cells by targeting FOSL1 and regulating the Wnt/beta-catenin pathway[J]. Ann Transl Med, 2022, 10(16): 893.
[28] Yan X,Yang P,Liu H,et al. miR-4461 inhibits the progression of Gallbladder carcinoma via regulating EGFR/AKT signaling[J]. Cell Cycle, 2022, 21(11): 1166-1177.
[29] Li X L,Li S Z,Wu C X,et al. miR-188-5p inhibits proliferation, migration, and invasion in gallbladder carcinoma by targeting Wnt2b and Smad2[J]. Kaohsiung J Med Sci, 2021, 37(4): 294-304.
[30] Wang W,Chen L C,Qian J Y,et al. MiR-335 promotes cell proliferation by inhibiting MEF2D and sensitizes cells to 5-Fu treatment in gallbladder carcinoma[J]. Eur Rev Med Pharmacol Sci, 2019, 23(22): 9829-9839.
[31] Gong Y Q,Ni J L,Fang Q,et al. MiR-1231 enhances docetaxel sensitivity to gallbladder carcinoma cells by downregulating FOXC2[J]. Eur Rev Med Pharmacol Sci, 2020, 24(23): 12116-12123.
[32] Yang G,Xu Q,Wan Y,et al. miR-193a-3p Enhanced the Chemosensitivity to Trametinib in Gallbladder Carcinoma by Targeting KRAS and Downregulating ERK Signaling[J]. Cancer Biother Radiopharm, 2021.